ANAGRELIDE SANDOZ®
(Anagrelide hydrochloride)
NOVARTIS
HK Reg. No. HK-68231
Composition:2
ANAGRELIDE SANDOZ® (anagrelide hydrochloride) is an inhibitor of cyclic AMP phosphodiesterase III. It is available in 0.5 mg hard capsule.
Indication:2
ANAGRELIDE SANDOZ® (anagrelide hydrochloride) is indicated for the reduction of elevated platelet counts in at risk
essential thrombocythemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy
References
1. AQUIPTA® (atogepant) EU Summary of Product Characteristics. August 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta. Accessed November 2023.
2. Anagrelide Sandoz 0.5 mg hard capsule - Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/10094/smpc#gref. 3. Amorolfine 5% w/v
Medicated Nail Lacquer (Legal category P) - Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/7414/smpc#gref.
